NOVAVAX (NVAX)
EARNINGS RELEASE - AUGUST 10 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.42/share REV: 39.58/M
___________________________________________________________
LAST QTR: EPS: -.70/share ACTUAL: -.58/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 1.35/share REV: 234.3/M
____________________________________________________________
FULL YR: EPS: 7.97/share REV: 1,100/M
____________________________________________________________
BEAT/MISS RECORD: 35% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 83.4, -12.9, 7.77
EXPECTED JUMP MOVE THIS QUARTER: 15-20%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before tradin
Links To Latest News and Headlines
Dr. Heather Yeo, SurvivorNet Medical Advisor & Associate Professor of Surgery and Associate Professor of Population Health Sciences at New York Presbyterian Weill Cornell Medicine, joins Yahoo Finance’s Kristin Myers to discuss the latest coronavirus updates.
Poland-based biotech firm Mabion has signed a preliminary agreement to manufacture Novavax Inc’s (NASDAQ: NVAX) COVID-19 vaccine, reports Bloomberg. The polish company will get 40 million zlotys ($11 million) in loans and equity from a state-run fund to support doubling its production capacity in Poland. Mabion will start commercial-scale production trials of Novavax shot. European Union countries such as Poland have struggled to secure supplies of COVID-19 vaccines sourced by Brussels, leading some to step up their efforts. It has also secured eight million doses of Novavax’s vaccine as part of EU joint purchases. The vaccine is yet to be approved by EU regulators. Mabion said it expects the technology transfer and verification to be complete by the middle of 2021. The country had to slow the pace of its vaccinations earlier this year due to supply shortfalls. Faced with a renewed surge in virus cases, Poland is now considering buying doses from China. Price Action: NVAX shares are down 3.6% at $198.6 in market trading hours on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaEU Considers Emergency Approvals To Boost COVID-19 Vaccine Rollout: ReutersEuropean Officials Seek To Garner Support For AstraZeneca COVID-19 Shot: CNBC© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Novavax said in January its coronavirus vaccine was 89.3% effective in a Phase 3 test. It’s also effective against variants. It’s now seeking authorization. Is NVAX stock a buy?
A vaccine shortage is on track to turn into a vaccine bounty in just a few months. The story of the Covid-19 vaccine rollout in the U.S., over the two and a half months since the first shots went into the first arms, has been one of scarcity. President said late Tuesday that there will be enough vaccine doses for every adult in the U.S. by the end of May. And by late spring or early summer, there could be an oversupply, according to a note out Tuesday by Jefferies analyst Michael Yee.
Novavax (NASDAQ: NVAX) has completed enrollment in its late-stage study of COVID-19 vaccine NVX-CoV2373 that’s being conducted in the U.S. and Mexico. In this Motley Fool Live video recorded on Feb. 24, 2021, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not there are any yellow flags with Novavax’s COVID-19 vaccine trial so far. Keith Speights: We have a question about Novavax’s vaccine technology.
StockJumpers analysis and trade plans are finalized and uploaded generally one house before market cloase (3PM EST) for most events unless noticed.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
Members who are too busy to manual trade can use Trade Assist. For more information visit here
| Avg Daily Volume: 8,831,772 Market Cap: 5.65B Sector: Healthcare Short Interest: 13.87 |
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.
by Team Stockjumpers